EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

The Role of Hematopoietic Cell Transplantation in Ataxia‐Telangiectasia

Laila Alkhouli iD, Seth Rotz iD, Masatoshi Takagi iD, Richa Sharma

Pediatric Blood & Cancer · 2026-08 · 73 (8)

DOI: 10.1002/1545-5017.70414 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 04.06.2026. Verfasst von Laila Alkhouli und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Hematology, Oncology, and Blood and Marrow Transplantation, Pediatric Institute, Cleveland Clinic Foundation, Cleveland, Ohio…. Hauptthemen laut MEDLINE: Ataxia Telangiectasia, Hematopoietic Stem Cell Transplantation, Transplantation Conditioning. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ataxia‐telangiectasia (A‐T) is a DNA repair disorder characterized by neurodegeneration, immunodeficiency, and cancer predisposition. Hematopoietic cell transplantation (HCT) is an established therapy in related disorders such as Fanconi anemia (FA) and Nijmegen breakage syndrome (NBS), but its role in A‐T is unclear. This comprehensive review describes the current literature exploring the indications for HCT in A‐T, focusing on conditioning regimens, outcomes, and toxicities.

Methods

A literature review of published A‐T HCT cases and preclinical studies was performed, analyzing conditioning regimens, immune reconstitution, complications, overall survival, and follow‐up.

Results

To date, 15 patients with A‐T who underwent HCT have been reported. Reduced‐intensity or FA‐adapted regimens were generally well tolerated and led to durable immune reconstitution, whereas myeloablative conditioning was associated with significant treatment‐related toxicities, including veno‐occlusive disease (VOD), graft‐versus‐host disease (GvHD), and hepatic failure. These clinical observations are supported by preclinical Atm ‐deficient mouse models demonstrating restoration of immune function and reduced lymphoma risk following HCT. Experience from related disorders, such as FA and NBS, further supports the use of radiation‐sparing, fludarabine‐based conditioning approaches in A‐T.

Conclusions

The use of HCT for the treatment of immunodeficiency and relapsed/refractory hematologic malignancies in patients with A‐T is not well described and understood. Current evidence is limited and heterogeneous, supporting its use only in select high‐risk patients at specialized centers, with multicenter collaboration needed to define best practices.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ataxia TelangiectasiaHematopoietic Stem Cell TransplantationTransplantation ConditioningHumansAnimals

Stichwörter der Autor:innen

DNA repair disordersataxia‐telangiectasiahematopoietic stem cell transplantationimmunodeficiencypediatric malignancy

Autor:innen und Institutionen

  • Department of Pediatric Hematology, Oncology, and Blood and Marrow Transplantation, Pediatric Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
  • Department of Pediatric and Developmental Biology, Institute of Science Tokyo, Tokyo, Japan.

ORCID-Profile: Laila Alkhouli, Seth Rotz, Masatoshi Takagi

Zitieren

APA

Alkhouli, L., Rotz, S., Takagi, M., & Sharma, R. (2026). The Role of Hematopoietic Cell Transplantation in Ataxia‐Telangiectasia. Pediatric Blood & Cancer, 73(8). https://doi.org/10.1002/1545-5017.70414

Vancouver

Alkhouli L, Rotz S, Takagi M, Sharma R. The Role of Hematopoietic Cell Transplantation in Ataxia‐Telangiectasia. Pediatric Blood & Cancer. 2026;73(8). doi:10.1002/1545-5017.70414

BibTeX
@article{Alkhouli2026,
  author = {Alkhouli, Laila and Rotz, Seth and Takagi, Masatoshi and Sharma, Richa},
  title = {The Role of Hematopoietic Cell Transplantation in Ataxia‐Telangiectasia},
  journal = {Pediatric Blood & Cancer},
  year = {2026},
  volume = {73},
  number = {8},
  doi = {10.1002/1545-5017.70414}
}
Kostenlos starten →